[Second Addendum to Commission A13-44 (ipilimumab, new therapeutic indication)]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018002999
German
Original Title:
2. Addendum zum Auftrag A13-44 (Ipilimumab, neues Anwendungsgebiet)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a14-15.html
Year Published:
2014
URL for published report:
https://www.iqwig.de/download/A14-15_Zweites-Addendum-zum-Auftrag-A13-44_Ipilimumab-neues-Anwendungsgebiet.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Melanoma
- Ipilimumab
- Immune Checkpoint Inhibitors
- Antineoplastic Agents, Immunological
- Antibodies, Monoclonal, Humanized
Keywords
- Ipilimumab
- Melanoma
- Benefit Assessment
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.